Ask AI
Immunotherapy Options in HNSCC

CE / CME

Driving Progress in HNSCC: Integrating Immunotherapy and Novel Targeted Therapies Across the Disease Continuum

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Released: June 05, 2025

Expiration: December 04, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In the phase III KEYNOTE-689 trial in patients with locally advanced HNSCC, for which population of patients was there an EFS benefit with the addition of perioperative pembrolizumab to SoC surgery + adjuvant radiotherapy ± cisplatin?

2.

Case 1: Patient With Metastatic HNSCC



  • 65-yr-old man treated 3 yr ago for T4N2 p16+ oropharynx cancer

  • Achieved a CR but now presents with bilateral lung nodules up to  1.8 cm in size

    • NavDX 38; CT-guided lung biopsy positive for p16+ squamous cell carcinoma; PD-L1 CPS 9



In your current practice, what would be your recommendation for this patient’s initial treatment?

3.

Case 2: Patient With Recurrent Middle Ear Effusions



  • A 49-yr-old man who is Cantonese speaking presents with recurrent left middle ear effusions

  • On physical exam:

    • Tympanostomy tube L

    • Palpable R sided level V adenopathy

    • Imaging obtained:






  • Core biopsy of the L level V LN obtained

  • Histopathologic findings:




  • PET CT shows extensive bone and liver metastases 

  • Patient has normal labs, no comorbidity and ECOG 0 

In your current practice, what would be your recommendation for this patient’s treatment?

4.

In your current practice, which approach would you recommend for a patient who develops grade 2 pneumonitis while on immune checkpoint inhibitor therapy?